Search PubMed⌕ Search

Biomedical subjects

Y Asano

Publications and source records attributed to Y Asano.

At least 793 records · Page 44Linked to original sources
PubMed1978

Avidity of anti-native DNA antibody and glomerular immune complex localization in lupus nephritis.

Ten patients with clinically active SLE and biopsy-proven renal involvement were studied. Antigen binding capacity (ABC) and avidity of anti-nDNA antibodies were measured, using 125I-nDNA, by the ammonium sulfate test of Minden and Farr. The glomerular localization of immune complexes was determined by morphological studies. Mean avidity in 7 patients with mesangial and subendothelial deposits was 0.387 +/- 0.022 (mean +/- SE), and in those with additional subepithelial deposits was 0.247 +/- 0.036 (P less than 0.01). When measured serially, the avidity was found to alter slowly either during treatment or spontaneously. Follow-up histology in 2 cases showed morphologic transitions; in one the transition from the initial mesangial proliferative type to the membranous form was associated with a shift of the avidity from a high level to a low one. There was no significant relation between the avidity and ABC (r = 0.235, P greater than 0.1), suggesting that avidity and the quantitative ABC of antibodies in immune complexes may not necessarily behave in parallel. Thus, the avidity measurement is useful in understanding the immunological events which underlie various clinicopathological features of SLE.

Adult↗
PubMed1978

Primary IgA glomerulonephritis and Schönlein-Henoch purpura nephritis: Clinicopathological and immunohistological characteristics.

A comparative analysis on clinicopathological and immunohistological characteristics was performed of 205 cases with primary IgA nephritis and 35 with Schönlein-Henoch purpura nephritis (purpura nephritis). Diagnostic criteria for primary IgA nephritis were set out so that IgA was either the most prominent immunoglobulin or, at least, equal to IgG and/or IgM, if present, irrespective of mesangial or peripheral localization. In primary IgA nephritis, one half of the cases were discovered by asymptomatic proteinuria, and one-third presented recurrent upper respiratory tract infection and gross hematuria, one-fourth abdominal pain and a few cases joint pain, while purpura nephritis was associated with a significantly higher incidence of such systemic symptoms as abdominal and joint pains, in addition to purpura. Both diseases shared a tendency toward conspicuous hematuria in contrast to the modest proteinuria, with normal renal function in three-fourths to two-thirds. Moreover, four of 35 with purpura nephritis showed preceding proteinuria and had been regarded as primary IgA nephritis until purpura appeared. The glomerular pathology had a common feature in that there was frequent occurrence of mesangial proliferative and focal and segmental lesions. The immunohistology in the two diseases was indistinguishable with regard to the glomerular immunoglobulins and mediators, whether purpura was present or absent. Thus, we propose a unifying concept that, by analogy with SLE, primary IgA nephritis may be regarded as 'sine lupo,' lying on one side of the nosological spectrum with less systemic symptoms, whereas purpura nephritis may occupy the other side with more systemic aspects. Furthermore, we confirmed the epimembranous granular deposition of IgA in both diseases as the most characteristic morphological expression of circulating immune complexes.

Adolescent↗
PubMed1978

Periodic psychosis recurring in association with menstrual cycle.

We reported seven cases of patients with regularly recurring psychosis in close association with the menstrual cycle, who showed certain characteristics in common in regard to their age of onset, clinical picture, psychogenic factors, endocrine and EEG findings. In these patients, monoamine metabolisms in the central nervous system, fluctuating in connection with menstrual cycle, may be disturbed by emotional impact or other unknown causes thereby delicately deranging the central nervous system activity, mentally and physiologically.

11-Hydroxycorticosteroids↗
PubMed1977

Protection against varicella in family contacts by immediate inoculation with live varicella vaccine.

A live varicella vaccine (Oka strain) was given to susceptible household contacts of varicella to test the protective efficacy of the vaccination. Twenty-six contacts of 21 families were vaccinated, usually within three days after onset of the index cases. None of the vaccinated children developed clinical symptoms of varicella. Eighteen of 24 sera obtained before vaccination were found to be seronegative by complement fixation and neutralization tests. Seroconversion was observed in all of the 18. On the other hand, all of 19 unvaccinated contacts in the 15 families, who served as controls, showed typical manifestations of varicella from 10 to 33 days after onset of the index varicella cases. In three families, where only one sibling contact received vaccine and the other was an unvaccinated control, none of the vaccinated children showed any clinical symptoms while unvaccinated controls exhibited typical varicella symptoms 10 to 14 days after the onset of the index cases. These results indicate that varicella is prevented in household contacts by vaccination within three days following exposure.

Antibody Formation↗
PubMed1977

Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward.

It was previously reported that a live varicella vaccine (Oka strain) has been developed and that the immediate vaccination of hospitalized children was effective for prevention of spread of varicella in a ward. Six to nine months later, there were four separate episodes of varicella and zoster in the same ward. Eighteen children (11 with nephrotic syndrome, 6 with nephritis, and 1 with hepatitis) with no history of varicella were inoculated with a live vaccine before or immediately after admittance or occurence of the varicella and zoster cases. Twelve of them had been receiving steroid therapy and 15 of the 18 were found to be seronegative by complement fixation and neutralization tests before the vaccination. All of them became seropositive after vaccination without any clinical symptoms. The longest period between vaccination and exposure was nine months. None of the vaccinees exhibited varicella symptoms after exposure. Serological follow-up of ten vaccinated children was done, and booster responses were observed in some of them after exposure. These results suggest that the live vaccine affords immunity to the recipients. If hospitalized children are vaccinated before or immediately after exposure, isolation of the patient is unnecessary.

Adolescent↗
PubMed1977

Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children.

A live varicella vaccine derived from the Oka strain was given on 181 children who had no history of varicella and were seronegative by complement fixation (CF) and neutralization (NT) tests; 125 children were hospitalized and 54 were receiving steroid therapy. Overall, seroconversion was achieved in 85.1% of the children by the CF test and in 97.8% by the NT test. Clinical reaction consisting of mild fever and rash appeared in only two children. One hundred seventy-nine of the vaccinated children were followed up by questionnaire and 51 were followed up serologically approximately two years later, at which time 10 of 51 (19.6%) were seropositive by the CF test and 50 of 51 (98.0%) by the NT test. Only one out of 80 children who had postvaccinal contact with varicella contracted mild varicella 16 months after vaccination. None of the vaccinees developed herpes zoster. These results suggest that this live varicella vaccine may safely and effectively be used for children with or without underlying diseases, including those receiving steroid therapy, and that immunity of at least two years' duration is conferred upon the vaccinated subjects.

Antibodies, Viral↗
PubMed1977

[Clinical experience with sustained release cephalexin (X-6437) (author's transl)].

Oral sustained release cephalexin (S-6437) was administered to 24 pediatric patients. Daily dose used was 18 approximately 60 mg/kg, which was divided into two doses and given after breakfast and dinner. The following are the results of the study. Out of 24 patients, 6 showed very good response, 10 good response, 6 fair, 1 poor and 1 unknown, Ratio of effectiveness was 69.6%. Two patients were reluctant to receive the drug and, therefore, they took other drugs. The other 22 patients, however, were easily given. No remarkable side effects due to S-6437 were found. From the above results, it was recognized that S-6437 has good effectiveness and safety, and it is convenient to give to children because the frequency of the drug administration is only twice a day.

Administration, Oral↗